B reast reconstruction is increasingly performed after mastectomy in women with breast cancer 1, 2 and for prophylaxis in women at high risk for breast cancer. Steadily increasing use of mastectomy in women with early breast cancer has been reported in the past decade, along with increasing use of bilateral mastectomy, even for unilateral disease. 3 Coinciding with this trend is increased use of immediate breast reconstruction (IR), particularly in women undergoing bilateral mastectomy, more than half of whom undergo reconstruction. 3, 4 Using the Nationwide Inpatient Sample, the proportion of women undergoing mastectomy for cancer or prophylaxis with IR increased by almost 1.5-fold from 28 .5% in 2005 to 42% in 2011 (M.A.O., unpublished data; November 2015). Immediate breast reconstruction is often recommended to women undergoing mastectomy because it is thought to confer psychosocial benefits and result in better cosmesis. 5 The true influence of reconstruction on quality of life is difficult to assess, because women who only undergo mastectomy tend to be older, white, have higher educational attainment, and place less importance on body image than women who undergo breast reconstruction. [6] [7] [8] [9] The perceived benefit of IR does not, however, take into account the potential for serious complications, including delays in initiating chemotherapy and radiotherapy that may affect the potential for cure, survival, quality of life, psychosocial well-being, return to work, and overall cost. The proportion of women with high-risk characteristics undergoing implant IR has increased 3-fold since the late 1990s, driven primarily by increased use of implant reconstruction. 10 Increased use of IR was found in all high-risk groups by Albornoz et al 10 using the National Cancer Database, including the elderly, women with advanced breast cancer, women with comorbidities, and women who required adjuvant radiotherapy.
Few studies with sufficient sample size in the literature compare wound complication rates, including surgical site infection (SSI) and noninfectious wound complications (NIWCs), to make firm conclusions about the relative incidence of complications after IR vs delayed reconstruction (DR). Given this paucity of data, we compared the incidence of wound complications after implant and/or autologous IR, DR, and secondary breast reconstruction (SR) using insurance claims data from nonelderly (aged 18-64 years) women. The goal of this study was to determine and compare complication rates to facilitate discussion of options with women considering breast reconstruction and the timing of reconstructive surgery after mastectomy (ie, IR vs DR).
Methods

Data
We conducted a retrospective cohort study using data from 12 Anthem-affiliated plans in the HealthCore Integrated Research Database, including individuals from 12 Anthemaffiliated plans (California, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri [excluding 30 counties in the Kansas
City area], Nevada, New Hampshire, New York, Ohio, and Virginia [excluding the northern suburbs of Washington, DC]). Data include all fully adjudicated claims submitted from clinicians, facilities, and outpatient pharmacies linked to health plan enrollment information. Fully insured women with enrollment in a fee-for-service plan and complete medical coverage were eligible for cohort inclusion. We excluded women with codes for end-stage renal disease, organ transplant, or human immunodeficiency virus owing to unique risk factors for complications. Medical claims were restricted to paid claims. This study was approved by the Washington University Human Research Protection Office, which did not require informed consent for this retrospective review of claims data.
Patient Population
We identified mastectomy operations among women aged 18 to 64 years from January 1, 2004, through December 31, 2011, using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and/or Current Procedural Terminology, 4th edition (CPT-4) procedure codes from inpatient and outpatient facility and clinician claims, as previously described. 11 We limited primary analyses to the first mastectomy per patient and the first subsequent reconstruction procedure within 365 days of mastectomy. We required at least 90 days of insurance coverage after the mastectomy and after the first DR or SR to identify SSIs and NIWCs. Patient characteristics, including demographic features, comorbidities, and cancer-related and operative factors, were defined as previously described. 12 
Procedure Dates and Definitions
Mastectomy and reconstruction dates within 7 days were collapsed into single-surgery dates because of potential date inaccuracy. 11 An implant or autologous breast reconstruction code within 7 days of the index mastectomy was considered IR. Breast reconstruction coded more than 7 days after the mastectomy date was considered to be a subsequent reconstruction, which we defined as delayed if the index mastectomy did not involve IR and secondary if the index mastectomy included IR.
Key Points
Question Does the incidence of wound complications differ after implant and autologous immediate, delayed, and secondary breast reconstruction?
Findings In this cohort study of 17 293 patients who underwent mastectomy, the incidence of surgical site infection was significantly higher after immediate (8.9%) compared with delayed (6.0%) and secondary (3.3%) implant reconstructions, with similar results for noninfectious wound complications. In contrast, the incidence of surgical site infection was similar after immediate (9.8%), delayed (13.9%), and secondary (11.6%) autologous reconstructions.
Meaning Delayed implant rather than immediate implant reconstruction may be beneficial in some high-risk patients to reduce the risk of wound complications.
Classification of Procedures
We classified mastectomy and IR as described previously. 
Identification and Timing of SSIs and NIWCs
We identified SSIs using a claims-based adaptation of the Centers for Disease Control and Prevention National Healthcare Safety Network definition of SSI. 13 We identified NIWCs (ie, tissue necrosis, dehiscence, hematoma, and fat necrosis) using ICD-9-CM diagnosis codes, as described previously.
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The time frame for identifying wound complications was limited to 2 to 90 days after each immediate, delayed, and secondary reconstructive operation (1-90 days for hematoma; hematomas can occur soon after the procedure) because we only required health insurance coverage through 90 days after each procedure. 
Identification of Chemotherapy and Radiotherapy
Adjuvant treatment was defined as having 2 or more distinct dates coded for radiotherapy or chemotherapy, as defined previously except for ICD-9-CM diagnosis codes for chemotherapy and radiotherapy and CPT-4 code 96402 for chemotherapy. 12 We examined the association of radiotherapy with complications after DR and SR, including only radiotherapy after mastectomy and before DR or SR. To examine the association of IR complications within 90 days with initiation of adjuvant chemotherapy and radiotherapy, we determined the time to first chemotherapy and/or radiotherapy treatment within 365 days of mastectomy, excluding women who had treatment initiation before a wound complication.
Statistical Analysis
Data were analyzed from January 
Overall Wound Complication Incidence After Reconstruction
The incidence of SSI and NIWCs within 90 days after IR, DR, and SR are shown in Table 1 Failed implant reconstruction, defined as implant removal or exchange within 60 days of insertion, occurred in 532 women (7.0%) after IR and 30 women (8.1%) after DR (P = .39). Among women with SSI, implant failure occurred in 300 IR (43.8%) and 12 DR procedures (57.1%; P = .23).
Influence of Wound Complications After IR
The association of SSI after implant IR with wound complications after SR is shown in Figure 2A . Figure 2A , the rates of NIWC and SSI after SR were significantly higher in women with an NIWC after implant IR (35 of 455 [7. 7%] and 42 of 455 [9.2%], respectively; P < .001) ( Figure 2B ). Compared with women without a wound complication after IR, women with IR-associated wound complications underwent significantly more breast procedures within 2 years after the index operation ( Table 2) . The difference in number of procedures after implant IR was greater in women with SSI (mean, 2.08; range, 0-9) and NIWCs (mean, 1.88; range, 0-9) vs women without a wound complication (1.37; range, 0-8) than in women after autologous IR with SSI (mean, 1.14; range, 0-6) and NIWCs (mean, 1.12; range, 0-6) vs women without a wound complication (mean of 0.87; range, 0-6). Women who had a wound complication after IR started chemotherapy 2 weeks later than women who did not have an IR wound complication (median start of chemotherapy, 53 vs 39 days after mastectomy; P < .001). Similarly, women who had a wound complication after IR had a median 3-week delay in initiation of radiotherapy compared with women who did not have a wound complication after IR (median start of radiotherapy, 162 vs 142 days after mastectomy; P < .001).
Association of Adjuvant Radiotherapy With Incidence of Wound Complications
Adjuvant radiotherapy was administered after mastectomy to 34 of 369 women before implant DR (9.2%) and 379 of 5665 women before implant SR (6.7%) ( Table 3) . Prior receipt of adjuvant radiotherapy was associated with approximately 2-fold higher incidence of wound complications after implant SR but was not associated with higher complication rates in women who underwent implant DR after adjuvant radiotherapy (Table 3 ). Among women who had subsequent autologous tissue reconstruction, 85 of 205 (41.5%) with autologous DR and 51 of 186 (27.4%) with autologous SR received adjuvant radiotherapy before the reconstruction. The incidence of any wound complication was not significantly different when comparing implant DR, autologous DR, or autologous SR according to receipt of adjuvant radiotherapy, although the number of women with complications in individual comparisons was very small (Table 3) .
Discussion
To our knowledge, this study is the largest to date comparing rates of SSI and NIWCs after immediate, delayed, and secondary breast reconstruction. We found that the incidence of wound complications was higher after implant IR than after implant DR or SR. In contrast, no difference was found in the incidence of complications after autologous IR com- pared with autologous DR or SR, although the number of procedures was smaller. Our finding of lower rates of wound complications after DR compared with IR is important because the women who had DR were more likely to have characteristics associated with a higher risk for SSI than were women who underwent IR (eg, tobacco use disorder, rural residence). 12 Thus, these women likely would have had even higher wound complication rates if they underwent immediate rather than delayed reconstruction. Wound complications after implant IR were associated with high rates of implant failure, and women who had wound complications after implant IR were also more likely have additional wound complications after secondary reconstructive procedures. Women who had a wound complication after IR underwent more subsequent breast procedures and had delayed adjuvant treatment initiation compared with women who did not have a wound complication after IR. Consensus is lacking in the literature regarding differences in complication rates after IR vs DR for autologous tissue flap and implant reconstructions. Several small studies [15] [16] [17] [18] have reported similar wound complication rates after autologous IR vs DR, whereas others 19, 20 have found higher complication rates after autologous IR. Sullivan and colleagues 15 reported a higher incidence of overall complications after implant IR compared with DR procedures, whereas 2 other groups 21, 22 reported no difference, although these studies included only a small number of implant DR procedures. Consistent with our finding of increased incidence of wound complications after implant IR vs implant SR, Lovecchio et al 23 and Cordeiro and McCarthy 22 reported significantly higher complication rates after implant IR compared with SR exchange procedures. In contrast to studies that did not find a difference in complication rates, our study was larger and we compared wound complication rates after implant IR vs SR within a woman using matched-pairs analysis to account for lack of independence of events. Several investigators [24] [25] [26] women with SSI more than 90 days after implant IR who had SR in the uninfected category, an additional 8 women had an SSI and 6 women had an NIWC after SR, bringing the total number of SSIs attributable to SR to 139 (2.9%) and the total number of NIWCs attributable to SR to 126 (2.6%). Compared with the incidence of SSI and NIWCs for women who had SSI within 90 days after implant IR, the differences remain statistically significant (P < .001). f NIWCs attributable to the immediate implant reconstruction were identified within 90 days of the index procedure. Follow-up to identify SR was performed through 365 days after mastectomy. g Indicates attributable to implant IR.
h If we included the 79 women with NIWCs more than 90 days after implant IR who had SR into the uncomplicated category, an additional 2 women had an SSI and 3 women had an NIWC after SR, bringing the total number of SSIs attributable to SR to 144 (3.0%) and the total number of NIWCs attributable to SR to 116 (2.4%). Compared with the incidence of SSI and NIWCs for women who had NIWCs within 90 days after implant IR, the differences remain statistically significant (P < .001).
lar field in which the initial implant is placed, compared with the surgical field at the time of delayed or second-stage implant insertion. 23 Another explanation for the higher complication rates is the longer operation times often required for IR owing to the performance of 2 sequential procedures. Women who developed an SSI after implant IR were more likely to have another SSI and/or an NIWC after any SR procedure. Similarly, NIWCs after implant IR were associated with a higher incidence of NIWCs and SSI after SR. Adkinson and colleagues 28 reported higher rates of complications and permanent implant loss after implant SR in women who had a complication after tissue expander insertion, although they did not report the secondary procedure complication risk according to the specific type of wound complication after the initial surgery. Thus, wound complications after implant IR appear to result in a prolonged risk for complications after subsequent procedures, possibly because of a poor softtissue envelope or continued low-level infection. An additional explanation may be that women who had a complication after their initial procedure had an inherently higher risk for complications and thus were more likely to have another complication after SR. We found that adjuvant radiotherapy was associated with higher SSI and NIWC rates after implant SR. Several investigators have reported higher rates of total complications with second-stage implants, 23 infection and wound breakdown, 29, 30 and reconstruction failure [29] [30] [31] [32] [33] [34] in women who received adjuvant radiotherapy after tissue expander or implant IR. In contrast, among women undergoing subsequent autologous reconstruction, we did not find increased rates of SSI or NIWCs after adjuvant radiotherapy. This finding is consistent with reports in the literature of the lack of association between radiotherapy and outcomes of autologous reconstruction.
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Limitations Claims data were designed for administrative purposes and have limitations, including misclassification of diagnoses and likely undercoding of SSIs and NIWCs, especially minor complications treated without additional procedures during the 90-day global surgical reimbursement period. 36 A previous study 37 reported the positive predictive values for identification of SSIs and NIWCs in this same population based on medical record review. Although the positive predictive value for SSI (57.5%) was lower than for a composite NIWC group (dehiscence or fat or tissue necrosis, 86.8%), most of the patients coded in error for SSI had a documented wound complication (most often cellulitis or an NIWC). Some of the procedures that we identified as SR may have been symmetry procedures on the contralat- eral side. Because the duration of continuous private insurance enrollment was variable, we limited our study to subsequent breast reconstruction within 1 year and complications within 90 days to limit loss to follow-up. Therefore, we are missing later complications and subsequent procedures and may be underestimating these rates. The incidence of complications after procedures performed from 2004 to 2011 may also underestimate the burden in the current era because of increased use of skin-and nipple areola complex-sparing mastectomy to optimize cosmesis, 38 with a potentially increased risk for complications.
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Conclusions
We found an increased incidence of infectious and noninfectious wound complications after immediate compared with delayed implant reconstruction, despite the higher risk profile of the population undergoing DR. Confirmation of these results in a prospective multicenter study that tracks individual outcomes in all settings will be important to verify the increased risk for wound complications after IR. Our finding of poorer outcomes associated with IR complications, including increased wound complication rates after the next reconstruction procedure, more subsequent breast procedures, and delay of the start of adjuvant treatment, underscores the need to communicate individualized complication risk to women considering IR. Consideration of the timing of implant reconstruction in relation to radiotherapy is also important. Our results suggest that some high-risk patients may benefit from delayed rather than immediate implant reconstruction or from the use of autologous reconstruction to decrease their risk for serious wound complications. Given trends of patients with increasingly medically complex problems undergoing breast reconstruction, tailoring of preventive measures to patients' unique risk factors and/or careful consideration of the best timing of reconstruction may be needed to prevent complications after immediate and subsequent breast reconstruction procedures. Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
